Vaccinal control of Marek's disease: current challenges, and future strategies to maximize protection.
about
Marek's disease virus and skin interactions.Modelling Marek's disease virus (MDV) infection: parameter estimates for mortality rate and infectiousnessDual infection and superinfection inhibition of epithelial skin cells by two alphaherpesviruses co-occur in the natural host.In vitro model for lytic replication, latency, and transformation of an oncogenic alphaherpesvirus.A mechanistic basis for potent, glycoprotein B-directed gammaherpesvirus neutralization.A herpesvirus ubiquitin-specific protease is critical for efficient T cell lymphoma formation.Marek's disease virus: lytic replication, oncogenesis and control.Mapping QTL affecting resistance to Marek's disease in an F6 advanced intercross population of commercial layer chickens.Integrated analyses of genome-wide DNA occupancy and expression profiling identify key genes and pathways involved in cellular transformation by a Marek's disease virus oncoprotein, Meq.Biomarker discovery in animal health and disease: the application of post-genomic technologies.Recombinant Marek's Disease Virus as a Vector-Based Vaccine against Avian Leukosis Virus Subgroup J in Chicken.In ovo evaluation of FloraMax®-B11 on Marek´s disease HVT vaccine protective efficacy, hatchability, microbiota composition, morphometric analysis, and Salmonella enteritidis infection in broiler chickens.Molecular evaluation of responses to vaccination and challenge by Marek's disease viruses.Chicken gga-miR-130a targets HOXA3 and MDFIC and inhibits Marek's disease lymphoma cell proliferation and migration.Telomerase-mediated apoptosis of chicken lymphoblastoid tumor cell line by lanthanum chloride.Molecular characterization of Marek's disease virus in a poultry layer farm from Colombia.Morphology of immune organs after very virulent plus strain of Marek's disease virus infection in vaccinated hens.Expression pattern of genes of RLR-mediated antiviral pathway in different-breed chicken response to Marek's disease virus infection.Real-time PCR for differential quantification of CVI988 vaccine virus and virulent strains of Marek's disease virus.The ORF012 gene of Marek's disease virus type 1 produces a spliced transcript and encodes a novel nuclear phosphoprotein essential for virus growth.Marek's disease viral interleukin-8 promotes lymphoma formation through targeted recruitment of B cells and CD4+ CD25+ T cellsThe effectiveness of mass vaccination on Marek's disease virus (MDV) outbreaks and detection within a broiler barn: a modeling study.Vaccination and reduced cohort duration can drive virulence evolution: Marek's disease virus and industrialized agriculture.Revaccination with Marek's disease vaccines induces productive infection and superior immunity.Development of a nested polymerase chain reaction method to detect oncogenic Marek's disease virus from feather tips.Correlation of Marek's disease herpesvirus vaccine virus genome load in feather tips with protection, using an experimental challenge model.Design of miRNA sponges for MDV-1 as a therapeutic strategy against lymphomas.Synergistic Viral Replication of Marek's Disease Virus and Avian Leukosis Virus Subgroup J is Responsible for the Enhanced Pathogenicity in the Superinfection of Chickens.
P2860
Q33646255-A84641CD-668B-4CDE-A932-C026C9CA57D8Q34073274-48233FBD-86A5-4182-80DD-9C0480E83E50Q34281878-B9862D09-B4AC-4C8F-BFBF-5067869A0219Q35740347-A8E4410B-A4E3-4F62-9949-0550BD1411D4Q35963823-CBBF8A94-0DC7-4581-BC68-8DBB1C3C4E6CQ36289021-18AFD84E-732A-4F7F-ACF2-20B6B882F63FQ36690269-804BEE52-7935-4E9C-BDE5-FB0FF5EAB71DQ37119020-2A074BE9-37EA-4209-9CAF-96308989F71CQ37123241-D2F98F9B-42D7-4381-BADF-C084082FFD5BQ37280937-B37AD922-5E0E-4F2A-9A1A-1BCD6CCF209AQ37450167-64DF2DFB-E7B6-4FAC-ACA0-B870DFA8D040Q38405695-DE58B9B0-970A-4655-9F43-FD0A9FF57754Q38440195-9E9EF9B7-F5BA-460B-9DA8-5502EF720EE9Q38447336-5045AF05-6AEE-4E60-AA78-DAB9A9B0BAEBQ39568532-9810A0AF-9B96-4AA5-9AB5-73392DFFFF4DQ40275332-592D6506-66A1-408C-A10D-3C1AD6E46931Q40589800-2C555B0A-0685-4988-8E71-E145EAD4E07CQ40726817-C0848FC3-7916-49B3-B68F-704D2F66ED0AQ40757072-A0050BDA-03D8-4608-A9C0-FAEBAE1CD28AQ41665276-1AE5B2AA-37A0-46CB-8481-4BE54C7FCE9DQ41818456-69AE7D01-7C8F-4B7F-8AD6-1F80CE417626Q41967372-171E9738-EE14-4157-B171-D9C48B5CEB38Q42272521-34150DB1-60D0-41CE-B6C8-9F80EBEB1CD2Q43179944-8A5FFB5C-7CD0-486C-BA0C-25C6C967E177Q44201340-54E94C2F-EA62-44A7-BA6B-F81CB43F61E0Q45399332-490C9D81-21A8-4044-B598-4E9FD82492C1Q48505142-A3308CDD-DED7-4528-A69B-FF84B69B26A7Q54204054-68F6FED4-2707-480F-8A1A-E081CCC4C994
P2860
Vaccinal control of Marek's disease: current challenges, and future strategies to maximize protection.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Vaccinal control of Marek's di ...... tegies to maximize protection.
@ast
Vaccinal control of Marek's di ...... tegies to maximize protection.
@en
type
label
Vaccinal control of Marek's di ...... tegies to maximize protection.
@ast
Vaccinal control of Marek's di ...... tegies to maximize protection.
@en
prefLabel
Vaccinal control of Marek's di ...... tegies to maximize protection.
@ast
Vaccinal control of Marek's di ...... tegies to maximize protection.
@en
P2093
P1476
Vaccinal control of Marek's di ...... ategies to maximize protection
@en
P2093
Lorraine P Smith
Richard J W Currie
Susan J Baigent
P356
10.1016/J.VETIMM.2006.03.014
P577
2006-05-08T00:00:00Z